• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.

作者信息

Tolaney Sara M, Toi Masakazu, Neven Patrick, Sohn Joohyuk, Grischke Eva-Maria, Llombart-Cussac Antonio, Soliman Hatem, Wang Hong, Wijayawardana Sameera, Jansen Valerie M, Litchfield Lacey M, Sledge George W

出版信息

Clin Cancer Res. 2022 Oct 14;28(20):4587. doi: 10.1158/1078-0432.CCR-22-2874.

DOI:10.1158/1078-0432.CCR-22-2874
PMID:36239018
Abstract
摘要

相似文献

1
Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.更正：循环肿瘤DNA中PIK3CA和ESR1突变的临床意义：来自阿贝西利联合氟维司群的MONARCH 2研究分析
Clin Cancer Res. 2022 Oct 14;28(20):4587. doi: 10.1158/1078-0432.CCR-22-2874.
2
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.阿贝西利联合氟维司群治疗激素受体阳性、人表皮生长因子受体 2 阴性的绝经前激素受体阳性晚期乳腺癌：MONARCH 2 试验的亚组分析。
Breast Cancer Res. 2021 Aug 23;23(1):87. doi: 10.1186/s13058-021-01463-2.
3
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.阿贝西利联合氟维司群治疗激素受体阳性、HER2 阴性乳腺癌的疗效：内分泌治疗进展后总生存的影响——MONARCH 2 随机临床试验
JAMA Oncol. 2020 Jan 1;6(1):116-124. doi: 10.1001/jamaoncol.2019.4782.
4
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.MONARCH 2 研究：阿贝西利联合氟维司群治疗 HR+/HER2-晚期乳腺癌患者的疗效，这些患者在接受内分泌治疗时发生了进展。
J Clin Oncol. 2017 Sep 1;35(25):2875-2884. doi: 10.1200/JCO.2017.73.7585. Epub 2017 Jun 3.
5
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.MONARCH 2 日本亚人群分析：一项 abemaciclib 联合氟维司群治疗激素受体阳性、人表皮生长因子受体 2 阴性乳腺癌的 III 期研究，该研究针对在内分泌治疗后进展的患者。
Breast Cancer. 2021 Sep;28(5):1038-1050. doi: 10.1007/s12282-021-01239-8. Epub 2021 Apr 1.
6
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.阿贝西利联合内分泌治疗 HR+/HER2-晚期乳腺癌的亚洲患者：MONARCH 2 和 3 研究。
Cancer Sci. 2021 Jun;112(6):2381-2392. doi: 10.1111/cas.14877. Epub 2021 May 1.
7
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR, HER2-Advanced Breast Cancer.MONARCH 2：接受阿贝西利联合氟维司群作为激素受体阳性、人表皮生长因子受体2阴性晚期乳腺癌一线和二线治疗患者的亚组分析
Clin Cancer Res. 2021 Nov 1;27(21):5801-5809. doi: 10.1158/1078-0432.CCR-20-4685. Epub 2021 Aug 10.
8
Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels.在MONARCH 2和MONARCH 3研究中接受阿贝西利治疗的日本晚期乳腺癌患者的安全性：对治疗中出现的中性粒细胞减少、腹泻以及丙氨酸转氨酶和天冬氨酸转氨酶水平升高的评估。
Cancer Manag Res. 2022 Mar 19;14:1179-1194. doi: 10.2147/CMAR.S348591. eCollection 2022.
9
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.血浆 ESR1 突变与雌激素受体阳性晚期乳腺癌的治疗。
J Clin Oncol. 2016 Sep 1;34(25):2961-8. doi: 10.1200/JCO.2016.67.3061. Epub 2016 Jun 6.
10
Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.根据治疗线，PIK3CA、AKT1 和 ESR1 基因的血浆无细胞 DNA 突变在 ER 阳性乳腺癌中的临床意义。
Mol Cancer. 2018 Feb 26;17(1):67. doi: 10.1186/s12943-018-0808-y.

引用本文的文献

1
Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectives.通过遗传、表观遗传和免疫调节机制解读乳腺癌治疗耐药性：从分子见解到转化前景
Cancer Drug Resist. 2025 Jul 21;8:36. doi: 10.20517/cdr.2025.69. eCollection 2025.
2
Druggable Molecular Networks in -Mutated Breast Cancer.-突变乳腺癌中的可药物作用分子网络
Biology (Basel). 2025 Mar 2;14(3):253. doi: 10.3390/biology14030253.
3
Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial.
激素受体阳性 HER2 阴性晚期乳腺癌中循环肿瘤细胞的预测：MONARCH 2 试验的回顾性分析。
Oncologist. 2024 Feb 2;29(2):123-131. doi: 10.1093/oncolo/oyad293.
4
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.转移性乳腺癌（MBC）患者中 ESR1/PIK3CA 密码子变异、致癌途径改变与临床表型之间的相互作用：全面的循环肿瘤 DNA（ctDNA）分析。
Breast Cancer Res. 2023 Oct 2;25(1):112. doi: 10.1186/s13058-023-01718-0.